BRPI0408240A - composto, utilização de um composto e composição farmacêutica - Google Patents

composto, utilização de um composto e composição farmacêutica

Info

Publication number
BRPI0408240A
BRPI0408240A BRPI0408240-0A BRPI0408240A BRPI0408240A BR PI0408240 A BRPI0408240 A BR PI0408240A BR PI0408240 A BRPI0408240 A BR PI0408240A BR PI0408240 A BRPI0408240 A BR PI0408240A
Authority
BR
Brazil
Prior art keywords
compound
carbon
pharmaceutical composition
hydrogen
formula
Prior art date
Application number
BRPI0408240-0A
Other languages
English (en)
Inventor
Thierry Bordet
Cyrille Drouot
Bruno Buisson
Original Assignee
Trophos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0302992A external-priority patent/FR2852246B1/fr
Priority claimed from FR0311324A external-priority patent/FR2860159B1/fr
Application filed by Trophos filed Critical Trophos
Publication of BRPI0408240A publication Critical patent/BRPI0408240A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSTO, UTILIZAçãO DE UM COMPOSTO E COMPOSIçãO FARMACêUTICA". Composto de fórmula I em que X = O ou grupamento N-OH, R representa um grupamento escolhido dentre o A = hidrogênio ou junto com B uma ligação carbono-carbono, B = hidrogênio, hidróxi ou junto com A uma ligação carbono-carbono, C, D, E, F = hidrogênio ou junto com D uma ligação carbono-carbono, ou um de seus sais de aditivo com os ácidos farmaceuticamente aceitáveis, com a exceção de alguns compostos, a título de medicamento, aplicação notadamente como neuroprotetores, novos compostos de fórmula I e composições farmacêuticas.
BRPI0408240-0A 2003-03-11 2004-03-05 composto, utilização de um composto e composição farmacêutica BRPI0408240A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0302992A FR2852246B1 (fr) 2003-03-11 2003-03-11 Utilisation de l'oxime de cholest-4-en-3-one dans le traitement des affections du motoneurone
FR0311324A FR2860159B1 (fr) 2003-09-26 2003-09-26 Utilisation de l'oxime de cholest-4-en-3-one en tant que medicament neuroprotecteur
PCT/FR2004/000532 WO2004082581A2 (fr) 2003-03-11 2004-03-05 Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives

Publications (1)

Publication Number Publication Date
BRPI0408240A true BRPI0408240A (pt) 2006-03-01

Family

ID=33031360

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408240-0A BRPI0408240A (pt) 2003-03-11 2004-03-05 composto, utilização de um composto e composição farmacêutica

Country Status (12)

Country Link
US (4) US7858603B2 (pt)
EP (1) EP1601363B1 (pt)
JP (1) JP4970932B2 (pt)
AU (1) AU2004222540B2 (pt)
BR (1) BRPI0408240A (pt)
CA (1) CA2517893C (pt)
DK (1) DK1601363T3 (pt)
ES (1) ES2388669T3 (pt)
IL (1) IL170348A (pt)
PL (1) PL1601363T3 (pt)
PT (1) PT1601363E (pt)
WO (1) WO2004082581A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874923B1 (fr) * 2004-09-07 2006-10-27 Trophos Sa Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
FR2894968B1 (fr) * 2005-12-20 2008-02-22 Trophos Sa Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
FR2899108B1 (fr) * 2006-03-31 2012-02-03 Trophos Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur
FR2907783A1 (fr) * 2006-10-30 2008-05-02 Trophos Sa Nouveaux composes chimiques, leurs procedes de synthese et leur utilisation a titre de medicament, particulierement a titre de medicament cytoprotecteur, neuroprotecteur ou cardioprotecteur
FR2914188B1 (fr) * 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
US20080275259A1 (en) * 2007-05-04 2008-11-06 Scinopharm Taiwan, Ltd Process for preparing aromatase inhibitors
AR061892A1 (es) * 2007-07-11 2008-10-01 Consejo Nac Invest Cient Tec Un compuesto que presenta actividad antiinflamatoria y actividad antiviral, composiciones farmaceuticas que lo comprenden, un procedimiento para su obtencion y uso del mismo en el tratamiento de la queratoconjuntivitis epidemica y de la queratitis estromal herpetica
FR2919180B1 (fr) * 2007-07-25 2009-11-27 Trophos Utilisation d'au moins un derive oxime de la cholest-4-en-3-one comme antioxydants
MX2010004859A (es) * 2007-10-30 2010-06-21 Trophos Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
AU2009219230A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
FR2934596B1 (fr) * 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用
US9447139B2 (en) 2010-04-09 2016-09-20 The Research Foundation Of State University Of New York Ship inhibitors and uses thereof
WO2012069150A2 (en) 2010-11-22 2012-05-31 Powerpore Gmbh Cytoprotectant agents for the prevention of drug-associated side-effects
FR2979239A1 (fr) 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
EP3978507A1 (en) * 2013-08-12 2022-04-06 Emory University Progesterone phosphate analogs and uses related thereto
US10758548B2 (en) * 2015-05-20 2020-09-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treating peripheral demyelinating diseases
AU2016353961B2 (en) * 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
WO2017207600A1 (en) 2016-06-03 2017-12-07 F. Hoffmann-La Roche Ag New treatment of sma
WO2018073141A1 (en) 2016-10-18 2018-04-26 F. Hoffmann-La Roche Ag New composition for treating sma
CN108938648A (zh) * 2018-06-21 2018-12-07 中山大学 胆甾-3,6-二酮用于神经元损伤的治疗
KR102812083B1 (ko) * 2021-12-01 2025-05-27 동국대학교 와이즈캠퍼스 산학협력단 3β, 6β-디-아세톡시-5-히드록시-5α-콜레스탄을 포함하는 신경세포 발달 촉진용 조성물 및 이를 이용한 신경세포 성장 촉진 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52116456A (en) * 1976-03-25 1977-09-29 Takasago Corp Preparation of 3-keto- #4-steroid
DE4004920C1 (pt) * 1990-02-16 1991-09-19 Kanoldt Arzneimittel Gmbh, 8884 Hoechstaedt, De
US5264428A (en) * 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
JPH0748397A (ja) * 1993-08-05 1995-02-21 Taisho Pharmaceut Co Ltd ステロイド化合物
ATE156836T1 (de) * 1994-05-19 1997-08-15 Akzo Nobel Nv 11,21-bisphenyl-19-nor-pregnan derivate
JP2001031572A (ja) * 1999-07-22 2001-02-06 Kyorin Pharmaceut Co Ltd ジクチオステロールを有効成分とする中枢神経細胞突起再生薬
DE19961219A1 (de) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法

Also Published As

Publication number Publication date
WO2004082581A2 (fr) 2004-09-30
EP1601363B1 (fr) 2012-06-20
DK1601363T3 (da) 2012-09-03
AU2004222540A1 (en) 2004-09-30
JP2006519819A (ja) 2006-08-31
IL170348A (en) 2014-02-27
AU2004222540B2 (en) 2009-10-01
US20100216752A1 (en) 2010-08-26
CA2517893C (fr) 2012-05-15
CA2517893A1 (fr) 2004-09-30
US8575138B2 (en) 2013-11-05
PL1601363T3 (pl) 2012-11-30
JP4970932B2 (ja) 2012-07-11
WO2004082581A3 (fr) 2004-10-28
US20120316141A1 (en) 2012-12-13
US7858603B2 (en) 2010-12-28
US8354395B2 (en) 2013-01-15
US20060217358A1 (en) 2006-09-28
PT1601363E (pt) 2012-08-17
EP1601363A2 (fr) 2005-12-07
US8283341B2 (en) 2012-10-09
US20120309721A1 (en) 2012-12-06
ES2388669T3 (es) 2012-10-17

Similar Documents

Publication Publication Date Title
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
SE0001899D0 (sv) New compounds
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
TR200103624T2 (tr) Amof bileşikler ve bunların farmasötik bileşimleri.
AR055319A1 (es) Derivados de isoquinoleina, composiciones farmaceuticas y usos
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0302496C1 (pt) composições farmacêuticas com atividade antibiótica
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]